Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease

Despite the fact that muscle weakness is a major problem in chronic obstructive pulmonary disease (COPD), detailed information on myopathological changes at the microscopic level in these patients is scarce, if indeed available at all. Vastus lateralis biopsies of 15 COPD weight-stable patients (body mass index (BMI) 23.9±1.0 kg·m−2; fat-free mass index (FFMI) 17.2±1.7 kg·m−2) and 16 healthy age-matched controls (BMI 26.3±0.8 kg·m−2; FFMI 19.6±2.2 kg·m−2) were evaluated. Histochemistry was used to evaluate myopathological features. Immunohistochemistry was used for the detection of macrophages and leukocytes, and active caspase 3 and terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labelling (TUNEL) as markers of apoptosis. Fatty cell replacement and fibrosis were observed in both groups, the latter being slightly, but significantly, more pronounced in COPD. No differences between COPD and controls were found with respect to central nuclei, necrosis, regeneration, or fibre splitting. Signs of mitochondrial abnormalities were absent and normal numbers of inflammatory cells were found. Active caspase 3 positive myocytes were not observed and no difference was found in the number of TUNEL-positive myonuclei between controls and COPD patients (1.1% versus 1.0%, respectively). The cross-sectional area of type-IIX muscle fibres was smaller in COPD than in controls (2,566 versus 4,248 µm2). Except for the I to IIX shift in fibre types, the selective type-IIX atrophy and a slight accompanying increase in fibrosis and fat cell replacement in chronic obstructive pulmonary disease relative to age-matched controls, no other morphological abnormalities were observed in the muscle biopsies of chronic obstructive pulmonary disease patients. Also, in this group of clinically and weight stable chronic obstructive pulmonary disease patients, apoptosis appeared not to be involved in muscle pathology.

[1]  H. van Mameren,et al.  Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. , 2002, The American journal of clinical nutrition.

[2]  H. van Mameren,et al.  Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[3]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[4]  S. Atiş,et al.  Subclinical peripheral neuropathy associated with chronic obstructive pulmonary disease. , 2001, Electromyography and clinical neurophysiology.

[5]  R. D. de Boer,et al.  Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. , 2000, Journal of cardiac failure.

[6]  R. Ferrari,et al.  Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes , 2000, Heart.

[7]  K. O'rourke,et al.  Myopathies in the elderly. , 2000, Rheumatic diseases clinics of North America.

[8]  M. Decramer,et al.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. , 2000, The American journal of clinical nutrition.

[9]  E. Wouters,et al.  Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. , 2000, The American journal of clinical nutrition.

[10]  V. Edgerton,et al.  Myonuclear domains in muscle adaptation and disease , 1999, Muscle & nerve.

[11]  E. Wouters,et al.  Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. , 1998, American Journal of Clinical Nutrition.

[12]  D. McConkey,et al.  Biochemical determinants of apoptosis and necrosis. , 1998, Toxicology letters.

[13]  F. Maltais,et al.  Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[14]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[15]  M. Decramer,et al.  Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[16]  J. Mege,et al.  Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[17]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[18]  E. Wouters,et al.  Body composition and exercise performance in patients with chronic obstructive pulmonary disease. , 1991, Thorax.

[19]  S. Heymsfield,et al.  Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. , 1990, The American journal of clinical nutrition.

[20]  P. Mezin,et al.  Microangiopathy of endoneurial vessels in hypoxemic chronic obstructive pulmonary disease (COPD) , 1989, Acta Neuropathologica.

[21]  A. Miller,et al.  Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.

[22]  M. Gardner,et al.  Statistical guidelines for contributors to medical journals. , 1983, British medical journal.

[23]  P. Wood,et al.  Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps. , 1980, WHO chronicle.

[24]  J. Rucker,et al.  Binocular Diplopia: A Practical Approach , 2005, The neurologist.

[25]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[26]  R. B. Young,et al.  Diseases and disorders of muscle. , 1993, Advances in food and nutrition research.

[27]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.